Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice
- 27 April 2015
- journal article
- Published by Elsevier BV in Journal of Clinical and Experimental Hepatology
- Vol. 5 (3), 190-198
- https://doi.org/10.1016/j.jceh.2015.02.005
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitusBMC Pharmacology and Toxicology, 2013
- Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitusBMC Pharmacology and Toxicology, 2013
- Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2American Journal of Physiology-Gastrointestinal and Liver Physiology, 2012
- As a Matter of FatCell Metabolism, 2009
- The Role of Peroxisome Proliferator-Activated Receptor γ Coactivator-1 β in the Pathogenesis of Fructose-Induced Insulin ResistanceCell Metabolism, 2009
- Inflammation and endoplasmic reticulum stress in obesity and diabetesInternational Journal of Obesity, 2008
- Consequences of Lipid Droplet Coat Protein Downregulation in Liver CellsDiabetes, 2008
- SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein KinaseJournal of Biological Chemistry, 2008
- MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesityJCI Insight, 2006
- The Chemistry behind Antioxidant Capacity AssaysJournal of Agricultural and Food Chemistry, 2005